Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase I Dose-finding Study of BI 754111 in Combination With BI 754091 in Patients With Advanced Solid Cancers Followed by Expansion Cohorts at the Selected Dose of the Combination in Patients With Non-small Cell Lung Cancer and Other Solid Tumors

NCT03156114 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT03156114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03156114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase I Dose-finding Study of BI 754111 in Combination With BI 754091 in Patients With Advanced Solid Cancers Followed by Expansion Cohorts at the Selected Dose of the Combination in Patients With Non-small Cell Lung Cancer and Other Solid Tumors
Lead sponsor
Boehringer Ingelheim
Phase
Phase 1
Overall status
Completed
Start date
June 13, 2017
Completion date
June 6, 2023
Enrollment
172 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, neoplasms